Skip to main content

Complicated Intra-Abdominal Infections

6
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 8 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
2
Ceftolozane/TazobactamPhase 3
MK0826, /Duration of Treatment : 8 WeeksPhase 3
Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal InfectionsN/A
MSD
MSDIreland - Ballydine
3 programs
2
Ceftolozane/TazobactamPhase 31 trial
MK0826, /Duration of Treatment : 8 WeeksPhase 31 trial
Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal InfectionsN/A1 trial
Active Trials
NCT00860587Unknown200Est. Oct 2009
NCT03830333Completed268Est. Oct 2020
NCT00389987Completed300Est. May 2004
Pfizer
PfizerNEW YORK, NY
2 programs
2
Ceftazidime -avibactamPhase 21 trial
ceftazidime/NXL104 + metronidazolePhase 2Small Molecule1 trial
Active Trials
NCT02475733Completed83Est. Jun 2017
NCT00752219Completed204Est. Dec 2009
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal InfectionsN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDCeftolozane/Tazobactam
MSDMK0826, /Duration of Treatment : 8 Weeks
PfizerCeftazidime -avibactam
Pfizerceftazidime/NXL104 + metronidazole
MSDAntibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections

Clinical Trials (5)

Total enrollment: 1,055 patients across 5 trials

NCT03830333MSDCeftolozane/Tazobactam

Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)

Start: Mar 2019Est. completion: Oct 2020268 patients
Phase 3Completed
NCT00389987MSDMK0826, /Duration of Treatment : 8 Weeks

Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

Start: Sep 2001Est. completion: May 2004300 patients
Phase 3Completed
NCT02475733PfizerCeftazidime -avibactam

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

Start: Aug 2015Est. completion: Jun 201783 patients
Phase 2Completed
NCT00752219Pfizerceftazidime/NXL104 + metronidazole

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

Start: Mar 2009Est. completion: Dec 2009204 patients
Phase 2Completed
NCT00860587MSDAntibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections

Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections

Start: Feb 2006Est. completion: Oct 2009200 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.